🇪🇺 Group R Rasagiline in European Union

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EMA authorised Group R Rasagiline on 21 February 2005

Marketing authorisation

EMA — authorised 21 February 2005

Application: EMEA/H/C/000574
Marketing authorisation holder: Teva B.V.
Local brand name: Azilect
Indication: Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.
Status: approved

Read official source →

Frequently asked questions

Is Group R Rasagiline approved in European Union?

Yes. EMA authorised it on 21 February 2005.

Who is the marketing authorisation holder for Group R Rasagiline in European Union?

Teva B.V. holds the EU marketing authorisation.